AEB 1102

Drug Profile

AEB 1102

Alternative Names: AEB1102; AERase; Co-ArgI-PEG - Aeglea Biotherapeutics; Co-ArgI-PEG modified human arginase I - Aeglea Biotherapeutics; Optimised human arginase I - Aeglea Biotherapeutics; PEG-arginase - Aeglea Biotherapeutics; Pegarginase - Aeglea Biotherapeutics

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Aeglea Biotherapeutics
  • Class Antineoplastics; Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Inborn urea cycle disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Inborn urea cycle disorders; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 08 Nov 2016 Pharmacodynamics data from a preclinical trial in Solid tumours released by Aeglea
  • 09 Aug 2016 AEB 1102 receives Orphan Drug status for Inborn urea cycle disorders in European Union
  • 18 Jul 2016 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV) , NCT02732184)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top